EyeGate Pharmaceuticals

EyeGate Pharmaceuticals develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system.

EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.